EW · 10-Q · 2026Q3

Edwards Lifesciences Corp

Filed 2026-11-04 · Healthcare · View original filing on EDGAR

Everything EW's SEC filings said, ranked

Ranked Events

• Income Tax Rate ChangesImportance 89 · Surprise 82
  The effective income tax rate for the nine months ended September 30, 2026 rose to 31.2% from 16.1% in 2025, an increase of 15.1 percentage points. A $174.4 million valuation allowance against deferred tax assets was…
• Intangible Asset ImpairmentImportance 77 · Surprise 82
  Edwards recorded $220.2 million of intangible and long-lived asset impairment charges in the three and nine months ended September 30, 2026. The charges primarily reflected the full impairment of an in-process research…
• VIE Investment ImpairmentImportance 71 · Surprise 82
  The company recorded a $163.6 million loss on impairment in the nine months ended September 30, 2026. The loss related to termination of an option agreement to acquire one VIE and a determination that the carrying…
• End-Market Demand TrendsImportance 70 · Surprise 56
  For the first nine months of 2026, TAVR net sales increased 11.1% year over year, primarily on higher sales of the Edwards SAPIEN platform, particularly SAPIEN 3 Ultra RESILIA. TMTT sales rose 47.7%, driven by PASCAL…
• Tax Litigation and ExposureImportance 64 · Surprise 42
  The IRS is pursuing material transfer-pricing adjustments concerning Surgical/TAVR intercompany transactions between Edwards’ United States and Switzerland subsidiaries. For tax years 2015–2017, the IRS sought $269.3…
• Capital Return ProgramImportance 58 · Surprise 42
  During the nine months ended September 30, 2026, Edwards repurchased 8.5 million shares for $696.6 million under its Board-authorized program. The purchases included a $500.0 million accelerated share repurchase…
• Revenue Performance and MixImportance 54 · Surprise 40
  Net sales for the nine months ended September 30, 2026 increased 13.5% to $5,105.1 million from $4,498.0 million, a $607.1 million gain. TAVR sales rose 11.1% to $3,697.2 million, TMTT sales rose 47.7% to $583.2…
• Acquisition / Partnership / DivestitureImportance 52 · Surprise 42
  Edwards acquired Autus Valve Technologies in February 2026 for total consideration of $128.9 million, including $35.1 million in cash funded from existing cash. Contingent payments for Autus may reach $132.5 million…
• Operating Cash Flow and CapexImportance 47 · Surprise 22
  Operating cash flow for the nine months ended September 30, 2026 was $1,266.0 million, up $121.7 million from the prior-year period, primarily because tax payments were lower, partly offset by higher working-capital…
• Medicare TAVR Coverage ExpansionImportance 44 · Surprise 60
  In September 2026, the Centers for Medicare & Medicaid Services updated its National Coverage Determination for transcatheter aortic valve replacement (TAVR). The change expands Medicare coverage to certain…
• Geographic Market CommentaryImportance 42 · Surprise 40
  For the first nine months of 2026, sales increased 11.9% in the United States, 17.0% in Europe, 4.4% in Japan, and 19.3% in Rest of World. Outside the United States, sales grew 15.8% overall. In the third quarter, Rest…
• Product Launch and TransitionImportance 38 · Surprise 60
  Edwards received FDA approval in January 2026 for the SAPIEN 3 transcatheter pulmonic valve delivery system, intended for pediatric and adult patients with congenital heart disease. In TMTT, the company received CE…
• Liquidity and Debt PositionImportance 37 · Surprise 6
  At September 30, 2026, cash and cash equivalents and short-term investments totaled $4.1 billion in the United States and $511.0 million outside the United States. Edwards had no borrowings under its $750.0 million…

Revenue by Product (in millions)

Revenue by Geography (in millions)